May 3, 2021 / Clinical Trials,Webinars

WATCH: Viltepso – A Treatment Option for Patients Amenable to Exon 53 Skipping (Webinar Recording)

NS Pharma joined PPMD for a webinar on April 22, 2021 to provide an update about VILTEPSO™, a treatment of Duchenne in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping, and its associated patient support program.

If you missed the live event, the recording can be found below.



Watch the Recording

Join Our Mailing List